Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy

Background : We have previously reported that repeated cycles of high-dose therapy (HDT), can be supported by unmanipulated autologous PBPC. Here we investigate whether purified CD34 + cells, obtained by immunomagnetic separation using the Isolex 300i device, can support such therapy. Methods : Twenty-nine consecutive patients with metastatic breast cancer had PBPC mobilized and harvested following chemotherapy and G-CSF (10 µg/kg per day). Patients with > 4.0 2 10 6 /kg CD34 + cells in the apheresis product underwent CD34-selection using the Isolex 300i (v2.0) device. All cells collected were equally divided into three aliquots and cryopreserved. Patients who did not achieve this threshold had unmanipulated cells collected and stored. Patients subsequently received three cycles of HDT with paclitaxel (175 mg/m 2), thiotepa (300 mg/m 2) and either ifosfamide (10 g/m 2) or cyclophosphamide (4 g/m 2). It was intended for patients to receive CD34-selected cells to support each of the three cycles of HDT (...